Related Experiment Video

Updated: Mar 19, 2026

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

6.1K

Angiogenesis in Colorectal Cancer: Antibodies

Emily Chan1

  • 1From the Vanderbilt University, Vanderbilt-Ingram Cancer Center, Nashville, TN.

Cancer Journal (Sudbury, Mass.)
|June 25, 2016
PubMed

Insights

Blockading angiogenesis, a key process in tumor growth, with vascular endothelial growth factor inhibitors has improved survival in metastatic colorectal cancer. This chapter reviews approved intravenous antiangiogenic agents for this disease.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Angiogenesis is essential for tumor growth and progression.
  • Vascular endothelial growth factor (VEGF) and its receptors are critical mediators of angiogenesis.
  • Targeting the angiogenesis pathway is a validated strategy in cancer therapy.

Purpose of the Study:

  • To review approved intravenous antiangiogenic agents for metastatic colorectal cancer (mCRC).
  • To discuss the role of these agents in the treatment of mCRC.

Main Methods:

  • Focus on intravenous antiangiogenic agents.
  • Review of approved therapies in metastatic colorectal cancer.

Main Results:

  • Blockade of angiogenesis has demonstrated efficacy in several tumor types.
  • Antiangiogenic agents have led to improved survival in mCRC.

Conclusions:

  • Intravenous antiangiogenic agents are important therapeutic options for metastatic colorectal cancer.
  • Targeting VEGF and its receptors offers a significant approach to mCRC treatment.

More Related Videos

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

7.2K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.5K